Clinical trials: Glial Tumors
Glioblastoma, Gliosarcoma
Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas
Objectives: To determine maximum tolerated dose of CPT-11 when administered following Temodar plus O6-benzylguanine To characterize any toxicity associated w combo of CPT-11 + Temodar plus O6-BG To observe pts for clinical…
- Trial name
- NCT00612638
- Testing
- Temodar, O6-BG, and Irinotecan
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Duke University
Low Grade Glioma (LGG), High Grade Glioma (HGG)
Confocal Laser Endomicroscopy for Brain Tumors
Confocal Laser Endomicroscopy (CLE) could be a useful tool for real-time diagnosis of brain lesions (initial diagnosis or follow-up post resection to check for residual dysplasia) and real-time assessment of resections margins…
- Trial name
- GLIOFOCAL (NCT02240758)
- Testing
- confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
High Grade Glioma, Glioma
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway.
- Conditions
- High Grade Glioma, Glioma, Glioma, Malignant, Glioblastoma
- Trial name
- NCT05773326
- Testing
- Temsirolimus
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Nader Sanai
Recurrent Glioblastoma
Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas
The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.
- Trial name
- NCT00586508
- Testing
- enzastaurin, bevacizumab, Enzyme-inducing antiepileptic drugs (EIAED)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Eli Lilly and Company
Glioma, Glioma, Malignant
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
The purpose of this research study is to see if a specific type of radiation therapy, called "proton pulsed reduced dose rate" or "PRDR radiotherapy" has any benefits at dose levels and number of fractions thought to be…
- Conditions
- Glioma, Glioma, Malignant, Recurrent Glioma
- Trial name
- POPCORN (NCT06397560)
- Testing
- PRDR
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Baptist Health South Florida
Brain and Central Nervous System Tumors
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent…
- Trial name
- NCT00002986
- Testing
- carmustine, topotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Epilepsy, Temporal Lobe, Temporal Lobe
Light Scattering Spectroscopy to Determine Brain Tumors
This study will use light scattering spectroscopy (LSS) to analyze brain tissue removed from patients during brain surgery to determine if this new technology can be used to differentiate between normal and cancerous cells.
- Trial name
- NCT00067418
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Venous Thromboembolism, Brain Tumors
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.
- Trial name
- NCT00135876
- Testing
- dalteparin
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 512 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Malignant Glioma, Glioblastoma Multiforme
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00024570
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- INSYS Therapeutics Inc
Anaplastic Oligoastrocytoma, Glioblastoma
A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
This study was to explore the effectiveness and safety of early TMZ chemotherapy between surgery and chemoradiotherapy plus the standard concomitant radiochemotherapy regimen.
- Trial name
- NCT05600491
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Glioblastoma
Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly…
- Trial name
- NCT02997423
- Where
- 19 sites in United States
- Volunteers
- 153 people
- Sponsor
- University of Iowa
Recurrent Glioblastoma
TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with…
- Trial name
- NCT03722342
- Testing
- TTAC-0001 and pembrolizumab combination
- Where
- 2 sites in Australia
- Volunteers
- 9 people
- Sponsor
- PharmAbcine
Brain Cancer, Brain Tumors
Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
The aim of the study "Fluorescence-guided resection of malignant gliomas with 5-Aminolevulinic acid (5-ALA) vs. conventional resection" is to determine how accurately contrast agent-accumulating tumour can be removed by primary…
- Conditions
- Brain Cancer, Brain Tumors, Cancer of Brain, Primary Brain Tumors
- Trial name
- NCT00241670
- Testing
- 5-aminolevulinic acid (5-ALA)
- Volunteers
- 415 people
- Sponsor
- medac GmbH
Melanoma (Skin), Melanoma Recurrent
Expanded Access for Pembrolizumab (MK-3475)
This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors.
- Conditions
- Melanoma (Skin), Melanoma Recurrent, Glioblastoma Multiforme, Glioblastoma by Gene Expression Profile
- Trial name
- NCT03311542
- Testing
- pembrolizumab
- Where
- 4 sites in Belarus, Hong Kong and 2 more
- Sponsor
- Center Trials & Treatment
Brain and Central Nervous System Tumors, Unspecified Adult Solid Tumor, Protocol Specific
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help solid tumor cells develop into normal cells.
- Trial name
- NCT00008086
- Testing
- calcitriol, carboplatin
- Where
- United States
- Sponsor
- University of Pittsburgh
Brain and Central Nervous System Tumors
Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus carmustine in treating patients who have…
- Trial name
- NCT00002988
- Testing
- carmustine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Duke University
Glioblastoma Multiforme
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme.
- Trial name
- NCT00704288
- Testing
- XL184
- Where
- 8 sites in United States
- Volunteers
- 222 people
- Sponsor
- Exelixis
Glioblastoma
18F-FluorThanatrace (PET/CT) in Glioblastoma
The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP…
- Trial name
- NCT04221061
- Testing
- 18F-FluorThanatrace
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Brain and Central Nervous System Tumors
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give…
- Trial name
- NCT00008008
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Advanced Cancer, Brain Involvement
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and…
- Trial name
- DM-CHOC-PEN (NCT01048008)
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- DEKK-TEC, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.